1. Evaluation of 12-Lipoxygenase (12-LOX) and Plasminogen Activator Inhibitor 1 (PAI-1) as Prognostic Markers in Prostate Cancer
    Tomasz Gondek et al, 2014, BioMed Research International CrossRef
  2. Synergy between molecular biology and imaging science toward mechanism-based biomarkers associated with prostate cancer
    Belinda Seto, 2012, JBiSE CrossRef
  3. Evaluation of alternative serum biomarkers to monitor the progression of chronic HBV and HCV infection
    S. Tsiomita et al, 2017, Infection, Genetics and Evolution CrossRef
  4. Effects of USPSTF guidelines on patterns of screening and treatment outcomes for prostate cancer
    Vindya Gunawardena, 2014, WJTM CrossRef
  5. Berberine targets epidermal growth factor receptor signaling to suppress prostate cancer proliferation in vitro
    ZHENG-HUA HUANG et al, 2015 CrossRef
  6. Molecular Signatures in Urologic Tumors
    Spencer Larkin et al, 2013, IJMS CrossRef
  7. The Role of Proteomics in Biomarker Development for Improved Patient Diagnosis and Clinical Decision Making in Prostate Cancer
    Claire Tonry et al, 2016, Diagnostics CrossRef
  8. null
    Gabriela Jurca et al, 2018 CrossRef
  9. Evaluation of prediction models for the staging of prostate cancer
    Susie Boyce et al, 2013, BMC Med Inform Decis Mak CrossRef
  10. Searching for the answer to cancer: New perspective may help to resolve an ageless conundrum
    Richard A. Watson, 2013, Urologic Oncology: Seminars and Original Investigations CrossRef
  11. Exploring glyoxalase 1 expression in prostate cancer tissues: Targeting the enzyme by ethyl pyruvate defangs some malignancy-associated properties
    Martin Baunacke et al, 2014, Prostate CrossRef
  12. Lectin approaches for glycoproteomics in FDA-approved cancer biomarkers
    Haitham A Badr et al, 2014, Expert Review of Proteomics CrossRef
  13. null
    Rajiv Lochan Gaur et al, 2014 CrossRef
  14. RETRACTED ARTICLE: ChIP-seq analysis of androgen receptor in LNCaP cell line
    Sifeng Tao et al, 2014, Mol Biol Rep CrossRef
  15. Biomarkers and personalized risk stratification for patients with clinically localized prostate cancer
    Pedro Costa-Pinheiro et al, 2014, Expert Review of Anticancer Therapy CrossRef
  16. The αvβ6Integrin Is Transferred Intercellularly via Exosomes
    Carmine Fedele et al, 2015, J. Biol. Chem. CrossRef
  17. Diagnostic and prognostic epigenetic biomarkers in cancer.
    Pedro Costa-Pinheiro et al, 2015, Epigenomics CrossRef
  18. null
    Benedikte Serruys et al, 2016 CrossRef
  19. Overexpression and purification of folded domain of prostate cancer related proteins MSMB and PSA
    Mohini Tiwary et al, 2016, Mol Biol Rep CrossRef
  20. Molecular analyses of prostate tumors for diagnosis of malignancy on fine-needle aspiration biopsies
    Menglin Shan et al, 2017, Oncotarget CrossRef
  21. An Update on the Prognostic and Predictive Serum Biomarkers in Metastatic Prostate Cancer
    Helen Saxby et al, 2020, Diagnostics CrossRef
  22. Clinical proteomics for prostate cancer: understanding prostate cancer pathology and protein biomarkers for improved disease management.
    Claire Tonry et al, 2020, Clin Proteomics CrossRef
  23. Bayesian adaptive design of early-phase clinical trials for precision medicine based on cancer biomarkers
    Shinjo Yada, 2021 CrossRef
  24. Multiplexed Prostate Cancer Companion Diagnostic Devices
    Josephine Aidoo-Brown et al, 2021, Sensors CrossRef
  25. Histologically benign PI‐RADS 4 and 5 lesions contain cancer‐associated epigenetic alterations
    Ceren Şeref et al, 2021, The Prostate CrossRef
  26. Current advances in prognostic and diagnostic biomarkers for solid cancers: Detection techniques and future challenges
    Mintu Pal et al, 2022, Biomedicine & Pharmacotherapy CrossRef
  27. null
    Mukesh Verma et al, 2019 CrossRef
  28. null
    Vinit Singh Baghel et al, 2023 CrossRef
  29. Protein Biomarker Detection in Prostate Cancer: A Comprehensive Review of Electrochemical Biosensors
    Hashmatullah Nasimi et al, 2023, Sensors and Actuators Reports CrossRef